Current pharmacological treatment approaches for alcohol dependence

Bibliography

• de Wit M, Jones DG, Sessler CN, et al. Alcohol-use disorders in the critically ill patient. Chest 2010;138(4):994-1003
   Google Scholar
• Boothby LA, Doering PL. Acamprosate for the treatment of alcohol dependence. Clin Ther 2005;27(6):695-714
   PubMed Web of Science ®Google Scholar
• Litten RZ, Egli M, Heilig M, et al. Medications development to treat alcohol dependence: a vision for the next decade. Addict Biol 2012;17(3):513-27
   PubMed Web of Science ®Google Scholar
• Mann K, Kiefer F, Spanagel R, Littleton J. Acamprosate: recent findings and future research directions. Alcohol Clin Exp Res 2008;32(7):1105-10
   PubMed Web of Science ®Google Scholar
• Spanagel R, Vengeliene V, Jandeleit B, et al. Acamprosate produces its anti-elapse effects via calcium. Neuropsychopharmacology 2013; doi: 10.1038/npp.2013.264. [Epub ahead of print]
   Google Scholar
• Rosner S, Hackl-Herrwerth A, Leucht S, et al. Acamprosate for alcohol dependence. Cochrane Database Syst Rev 2010(9):CD004332
   Google Scholar
• Rosner S, Hackl-Herrwerth A, Leucht S, et al. Opioid antagonists for alcohol dependence. Cochrane Database Syst Rev 2010(12):CD001867
   PubMed Web of Science ®Google Scholar
• Anton RF, O'Malley SS, Ciraulo DA, et al. Combined pharmacotherapies and behavioral interventions for alcohol dependence: the COMBINE study: a randomized controlled trial. JAMA 2006;295(17):2003-17
   PubMed Web of Science ®Google Scholar
• Mann K, Lemenager T, Hoffmann S, et al. Results of a double-blind, placebo-controlled pharmacotherapy trial in alcoholism conducted in Germany and comparison with the US COMBINE study. Addict Biol 2013;18(6):937-46
   PubMed Web of Science ®Google Scholar
• Suh JJ, Pettinati HM, Kampman KM, O'Brien CP. The status of disulfiram: a half of a century later. J Clin Psychopharmacol 2006;26(3):290-302
   PubMed Web of Science ®Google Scholar
• Jorgensen CH, Pedersen B, Tonnesen H. The efficacy of disulfiram for the treatment of alcohol use disorder. Alcohol Clin Exp Res 2011;35(10):1749-58
   PubMed Web of Science ®Google Scholar
• Niederhofer H, Staffen W. Comparison of disulfiram and placebo in treatment of alcohol dependence of adolescents. Drug Alcohol Rev 2003;22(3):295-7
   PubMed Web of Science ®Google Scholar
• Fuller RK, Roth HP. Disulfiram for the treatment of alcoholism. An evaluation in 128 men. Ann Intern Med 1979;90(6):901-4
   PubMed Web of Science ®Google Scholar
• Fuller RK, Branchey L, Brightwell DR, et al. Disulfiram treatment of alcoholism. A Veterans Administration cooperative study. JAMA 1986;256(11):1449-55
   PubMed Web of Science ®Google Scholar
• Pani PP, Trogu E, Vacca R, et al. Disulfiram for the treatment of cocaine dependence. Cochrane Database Syst Rev 2010(1):CD007024
   Google Scholar
• Vaccari A, Saba PL, Ruiu S, et al. Disulfiram and diethyldithiocarbamate intoxication affects the storage and release of striatal dopamine. Toxicol Appl Pharmacol 1996;139(1):102-8
   PubMed Web of Science ®Google Scholar
• Muller CA, Banas R. Disulfiram: an anticraving substance? Am J Psychiatry 2011;168(1):98; author reply -9
   Google Scholar
• Weinshenker D. Cocaine sobers up. Nat Med 2010;16(9):969-70
   Google Scholar
• Bart G, Schluger JH, Borg L, et al. Nalmefene induced elevation in serum prolactin in normal human volunteers: partial kappa opioid agonist activity? Neuropsychopharmacology 2005;30(12):2254-62
   PubMed Web of Science ®Google Scholar
• Mason BJ, Ritvo EC, Morgan RO, et al. A double-blind, placebo-controlled pilot study to evaluate the efficacy and safety of oral nalmefene HCl for alcohol dependence. Alcohol Clin Exp Res 1994;18(5):1162-7
   PubMed Web of Science ®Google Scholar
• Mason BJ, Salvato FR, Williams LD, et al. A double-blind, placebo-controlled study of oral nalmefene for alcohol dependence. Arch Gen Psychiatry 1999;56(8):719-24
   PubMed Web of Science ®Google Scholar
• Karhuvaara S, Simojoki K, Virta A, et al. Targeted nalmefene with simple medical management in the treatment of heavy drinkers: a randomized double-blind placebo-controlled multicenter study. Alcohol Clin Exp Res 2007;31(7):1179-87
   PubMed Web of Science ®Google Scholar
• Anton RF, Pettinati H, Zweben A, et al. A multi-site dose ranging study of nalmefene in the treatment of alcohol dependence. J Clin Psychopharmacol 2004;24(4):421-8
   PubMed Web of Science ®Google Scholar
• Mann K, Bladstrom A, Torup L, et al. Extending the treatment options in alcohol dependence: a randomized controlled study of as-needed nalmefene. Biol Psychiatry 2013;73(8):706-13
   PubMed Web of Science ®Google Scholar
• Gual A, He Y, Torup L, et al. A randomised, double-blind, placebo-controlled, efficacy study of nalmefene, as-needed use, in patients with alcohol dependence. Eur Neuropsychopharmacol 2013;23(11):1432-42
   PubMed Web of Science ®Google Scholar
• European Medicines Agency (EMA). 2013. Available from: http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/002583/human_med_001620.jsp&mid=WC0b01ac058001d124 [Accessed 18 September 2013]
   Google Scholar
• Bennett B, Lamberty Y, Bizot JC, et al. Levetiracetam prevents signs of alcohol withdrawal in mice [abstract NR689]. New Research Program and Abstracts of the 156th Annual Meeting of the American Psychiatric Association; 21 May 2003; San Francisco; 2003. p. 58
   Google Scholar
• Muller CA, Schafer M, Schneider S, et al. Efficacy and safety of levetiracetam for outpatient alcohol detoxification. Pharmacopsychiatry 2010;43(5):184-9
   Google Scholar
• Gower AJ, Noyer M, Verloes R, et al. ucb L059, a novel anti-convulsant drug: pharmacological profile in animals. Eur J Pharmacol 1992;222(2-3):193-203
   Web of Science ®Google Scholar
• Noyer M, Gillard M, Matagne A, et al. The novel antiepileptic drug levetiracetam (ucb L059) appears to act via a specific binding site in CNS membranes. Eur J Pharmacol 1995;286(2):137-46
   PubMed Web of Science ®Google Scholar
• Margineanu DG, Klitgaard H. Levetiracetam has no significant gamma-aminobutyric acid-related effect on paired-pulse interaction in the dentate gyrus of rats. Eur J Pharmacol 2003;466(3):255-61
   Google Scholar
• Fuks B, Gillard M, Michel P, et al. Localization and photoaffinity labelling of the levetiracetam binding site in rat brain and certain cell lines. Eur J Pharmacol 2003;478(1):11-19
   Google Scholar
• Lynch BA, Lambeng N, Nocka K, et al. The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam. Proc Natl Acad Sci USA 2004;101(26):9861-6
   PubMed Web of Science ®Google Scholar
• Gillard M, Chatelain P, Fuks B. Binding characteristics of levetiracetam to synaptic vesicle protein 2A (SV2A) in human brain and in CHO cells expressing the human recombinant protein. Eur J Pharmacol 2006;536(1-2):102-8
   PubMed Web of Science ®Google Scholar
• Stahl SM. Psychopharmacology of anticonvulsants: levetiracetam as a synaptic vesicle protein modulator. J Clin Psychiatry 2004;65(9):1162-3
   Google Scholar
• Bennett B, Lamberty Y, Bizot JC, et al. Levetiracetam prevents signs of alcohol withdrawal in mice [abstract NR689]. New Research Program and Abstracts of the 156th Annual Meeting of the American Psychiatric Association; 21 May 2003; San Francisco; 2003. p. 58
   Google Scholar
• Krebs M, Leopold K, Richter C, et al. Levetiracetam for the treatment of alcohol withdrawal syndrome: an open-label pilot trial. J Clin Psychopharmacol 2006;26(3):347-9
   PubMedGoogle Scholar
• Richter C, Hinzpeter A, Schmidt F, et al. Levetiracetam for the treatment of alcohol withdrawal syndrome: a multicenter, prospective, randomized, placebo-controlled trial. J Clin Psychopharmacol 2010;30(6):720-5
   Google Scholar
• Richter C, Effenberger S, Bschor T, et al. Efficacy and safety of levetiracetam for the prevention of alcohol relapse in recently detoxified alcohol-dependent patients: a randomized trial. J Clin Psychopharmacol 2012;32(4):558-62
   PubMed Web of Science ®Google Scholar
• Fertig JB, Ryan ML, Falk DE, et al. A double-blind, placebo-controlled trial assessing the efficacy of levetiracetam extended-release in very heavy drinking alcohol-dependent patients. Alcohol Clin Exp Res 2012;36(8):1421-30
   PubMed Web of Science ®Google Scholar
• Johnson BA. Recent advances in the development of treatments for alcohol and cocaine dependence: focus on topiramate and other modulators of GABA or glutamate function. CNS Drugs 2005;19(10):873-96
   PubMedGoogle Scholar
• White HS, Brown SD, Woodhead JH, et al. Topiramate modulates GABA-evoked currents in murine cortical neurons by a nonbenzodiazepine mechanism. Epilepsia 2000;41(Suppl 1):S17-20
   PubMed Web of Science ®Google Scholar
• Moghaddam B, Bolinao ML. Glutamatergic antagonists attenuate ability of dopamine uptake blockers to increase extracellular levels of dopamine: implications for tonic influence of glutamate on dopamine release. Synapse 1994;18(4):337-42
   Google Scholar
• Farook JM, Lewis B, Littleton JM, Barron S. Topiramate attenuates the stress-induced increase in alcohol consumption and preference in male C57BL/6J mice. Physiol Behav 2009;96(1):189-93
   Google Scholar
• Nguyen SA, Malcolm R, Middaugh LD. Topiramate reduces ethanol consumption by C57BL/6 mice. Synapse 2007;61(3):150-6
   PubMed Web of Science ®Google Scholar
• Johnson BA, Ait-Daoud N, Bowden CL, et al. Oral topiramate for treatment of alcohol dependence: a randomised controlled trial. Lancet 2003;361(9370):1677-85
   PubMed Web of Science ®Google Scholar
• Johnson BA, Rosenthal N, Capece JA, et al. Topiramate for treating alcohol dependence: a randomized controlled trial. JAMA 2007;298(14):1641-51
   PubMed Web of Science ®Google Scholar
• Baltieri DA, Daro FR, Ribeiro PL, de Andrade AG. Comparing topiramate with naltrexone in the treatment of alcohol dependence. Addiction 2008;103(12):2035-44
   Google Scholar
• Rubio G, Martinez-Gras I, Manzanares J. Modulation of impulsivity by topiramate: implications for the treatment of alcohol dependence. J Clin Psychopharmacol 2009;29(6):584-9
   Google Scholar
• Furieri FA, Nakamura-Palacios EM. Gabapentin reduces alcohol consumption and craving: a randomized, double-blind, placebo-controlled trial. J Clin Psychiatry 2007;68(11):1691-700
   PubMed Web of Science ®Google Scholar
• Mason BJ, Quello S, Goodell V, et al. Gabapentin treatment for alcohol dependence: a randomized clinical trial. JAMA Intern Med 2013. doi: 10.1001/jamainternmed.2013.11950. [Epub ahead of print]
   Google Scholar
• Davidoff RA. Antispasticity drugs: mechanisms of action. Ann Neurol 1985;17(2):107-16
   PubMed Web of Science ®Google Scholar
• Bowery NG, Hudson AL, Price GW. GABAA and GABAB receptor site distribution in the rat central nervous system. Neuroscience 1987;20(2):365-83
   PubMed Web of Science ®Google Scholar
• Fadda P, Scherma M, Fresu A, et al. Baclofen antagonizes nicotine-, cocaine-, and morphine-induced dopamine release in the nucleus accumbens of rat. Synapse 2003;50(1):1-6
   PubMed Web of Science ®Google Scholar
• Heinz A. Dopaminergic dysfunction in alcoholism and schizophrenia–psychopathological and behavioral correlates. Eur Psychiatry 2002;17(1):9-16
   Google Scholar
• Colombo G, Serra S, Brunetti G, et al. The GABA(B) receptor agonists baclofen and CGP 44532 prevent acquisition of alcohol drinking behaviour in alcohol-preferring rats. Alcohol Alcohol 2002;37(5):499-503
   Google Scholar
• Daoust M, Saligaut C, Lhuintre JP, et al. GABA transmission, but not benzodiazepine receptor stimulation, modulates ethanol intake by rats. Alcohol 1987;4(6):469-72
   Google Scholar
• Colombo G, Serra S, Brunetti G, et al. Suppression by baclofen of alcohol deprivation effect in Sardinian alcohol-preferring (sP) rats. Drug Alcohol Depend 2003;70(1):105-8
   Google Scholar
• Anstrom KK, Cromwell HC, Markowski T, Woodward DJ. Effect of baclofen on alcohol and sucrose self-administration in rats. Alcohol Clin Exp Res 2003;27(6):900-8
   Google Scholar
• Besheer J, Lepoutre V, Hodge CW. GABA(B) receptor agonists reduce operant ethanol self-administration and enhance ethanol sedation in C57BL/6J mice. Psychopharmacology (Berl) 2004;174(3):358-66
   PubMed Web of Science ®Google Scholar
• Addolorato G, Caputo F, Capristo E, et al. Baclofen efficacy in reducing alcohol craving and intake: a preliminary double-blind randomized controlled study. Alcohol Alcohol 2002;37(5):504-8
   PubMed Web of Science ®Google Scholar
• Addolorato G, Leggio L, Ferrulli A, et al. Effectiveness and safety of baclofen for maintenance of alcohol abstinence in alcohol-dependent patients with liver cirrhosis: randomised, double-blind controlled study. Lancet 2007;370(9603):1915-22
   PubMed Web of Science ®Google Scholar
• Garbutt JC, Kampov-Polevoy AB, Gallop R, et al. Efficacy and safety of baclofen for alcohol dependence: a randomized, double-blind, placebo-controlled trial. Alcohol Clin Exp Res 2010;34(11):1849-57
   PubMed Web of Science ®Google Scholar
• Addolorato G, Leggio L, Ferrulli A, et al. Dose-response effect of baclofen in reducing daily alcohol intake in alcohol dependence: secondary analysis of a randomized, double-blind, placebo-controlled trial. Alcohol Alcohol 2011;46(3):312-17
   PubMed Web of Science ®Google Scholar
• Agabio R, Preti A, Gessa GL. Efficacy and tolerability of baclofen in substance use disorders: a systematic review. Eur Addict Res 2013;19(6):325-45
   PubMed Web of Science ®Google Scholar
• Ericson M, Lof E, Stomberg R, Soderpalm B. The smoking cessation medication varenicline attenuates alcohol and nicotine interactions in the rat mesolimbic dopamine system. J Pharmacol Exp Ther 2009;329(1):225-30
   Google Scholar
• Mitchell JM, Teague CH, Kayser AS, et al. Varenicline decreases alcohol consumption in heavy-drinking smokers. Psychopharmacology (Berl) 2012;223(3):299-306
   PubMed Web of Science ®Google Scholar
• Fucito LM, Toll BA, Wu R, et al. A preliminary investigation of varenicline for heavy drinking smokers. Psychopharmacology (Berl) 2011;215(4):655-63
   PubMed Web of Science ®Google Scholar
• Plebani JG, Lynch KG, Rennert L, et al. Results from a pilot clinical trial of varenicline for the treatment of alcohol dependence. Drug Alcohol Depend 2013;133(2):754-8
   PubMed Web of Science ®Google Scholar
• Litten RZ, Ryan ML, Fertig JB, et al. A double-blind, placebo-controlled trial assessing the efficacy of varenicline tartrate for alcohol dependence. J Addict Med 2013;7(4):277-86
   PubMed Web of Science ®Google Scholar
• Rasmussen DD, Alexander LL, Raskind MA, Froehlich JC. The alpha1-adrenergic receptor antagonist, prazosin, reduces alcohol drinking in alcohol-preferring (P) rats. Alcohol Clin Exp Res 2009;33(2):264-72
   Google Scholar
• Simpson TL, Saxon AJ, Meredith CW, et al. A pilot trial of the alpha-1 adrenergic antagonist, prazosin, for alcohol dependence. Alcohol Clin Exp Res 2009;33(2):255-63
   PubMed Web of Science ®Google Scholar
• Tomkins DM, Le AD, Sellers EM. Effect of the 5-HT3 antagonist ondansetron on voluntary ethanol intake in rats and mice maintained on a limited access procedure. Psychopharmacology (Berl) 1995;117(4):479-85
   PubMed Web of Science ®Google Scholar
• Johnson BA, Roache JD, Javors MA, et al. Ondansetron for reduction of drinking among biologically predisposed alcoholic patients: a randomized controlled trial. JAMA 2000;284(8):963-71
   PubMed Web of Science ®Google Scholar
• Johnson BA, Ait-Daoud N, Seneviratne C, et al. Pharmacogenetic approach at the serotonin transporter gene as a method of reducing the severity of alcohol drinking. Am J Psychiatry 2011;168(3):265-75
   PubMed Web of Science ®Google Scholar
• Johnson BA, Seneviratne C, Wang XQ, et al. Determination of genotype combinations that can predict the outcome of the treatment of alcohol dependence using the 5-HT(3) antagonist ondansetron. Am J Psychiatry 2013;170(9):1020-31
   PubMed Web of Science ®Google Scholar
• Correa Filho JM, Baltieri DA. A pilot study of full-dose ondansetron to treat heavy-drinking men withdrawing from alcohol in Brazil. Addict Behav 2013;38(4):2044-51
   Google Scholar
• Johnson BA, Rosenthal N, Capece JA, et al. Improvement of physical health and quality of life of alcohol-dependent individuals with topiramate treatment: US multisite randomized controlled trial. Arch Intern Med 2008;168(11):1188-99
   PubMedGoogle Scholar
• European Association for the Study of Liver. EASL clinical practical guidelines: management of alcoholic liver disease. J Hepatol 2012;57(2):399-420
   PubMed Web of Science ®Google Scholar
• Colombo G, Vacca G, Serra S, et al. Baclofen suppresses motivation to consume alcohol in rats. Psychopharmacology (Berl) 2003;167(3):221-4
   Web of Science ®Google Scholar
• Ameisen O. Complete and prolonged suppression of symptoms and consequences of alcohol-dependence using high-dose baclofen: a self-case report of a physician. Alcohol Alcohol 2005;40(2):147-50
   PubMed Web of Science ®Google Scholar
• Bucknam W. Suppression of symptoms of alcohol dependence and craving using high-dose baclofen. Alcohol Alcohol 2007;42(2):158-60
   PubMed Web of Science ®Google Scholar
• Miller NS, Gold MS. Comorbid cigarette and alcohol addiction: epidemiology and treatment. J Addict Dis 1998;17(1):55-66
   PubMed Web of Science ®Google Scholar